期刊文献+

托吡酯对奥氮平所致体质量增加的影响 被引量:6

下载PDF
导出
摘要 目的探讨托吡酯防治奥氮平所致体质量增加的效果。方法将41例首发精神分裂症患者随机分为实验组和对照组,实验组21例,应用奥氮平及托吡酯治疗;对照组20例,应用奥氮平及安慰剂治疗。于治疗前及治疗第4、8、10周末测定体质量、身高、腰围、臀围,计算体质量指数(BMI)、腰臀比(WHR),及计算治疗第10周末体质量增加>7%的比率。结果治疗第10周末,两组的体质量、BMI较治疗前均升高(<0.01),实验组的WHR较治疗前无明显升高。对照组的体质量、BMI和WHR的变化值高于实验组(<0.01);对照组体质量增加>7%的比率高于实验组(<0.01)。结论托吡酯在控制奥氮平所致体质量增加有一定的疗效。
出处 《现代实用医学》 2012年第9期979-980,共2页 Modern Practical Medicine
  • 相关文献

参考文献9

二级参考文献29

  • 1刘燕,李华芳,王慧芳,王克勋,高哲石,顾牛范.氯氮平、利培酮对精神分裂症病人血糖-胰岛素稳态的影响及相关因素分析[J].上海精神医学,2003,15(5):257-259. 被引量:33
  • 2Poyurovsky M, Pashinian A, Gil-Ad I, et al. Olanzapine-induced weight gain in patients with first-episode schizophrenia: a double-blind, placebo-controlled study of fluoxetine addition. Am J Psychiatry, 2002, 159 : 1058-1060.
  • 3Smith RC, Lindenmayer JP, Bark N, et al. Clozapine, risperidone, olanzapine, and conventional antipsychotic drug effects on glucose, lipids, and leptin in schizophrenic patients. Int J Neuropsychopharmacol, 2005, 8 : 183-194.
  • 4Allison DB, Mentore JL, Heo M, et al. Antipsychotic-induced weight gain : a comprehensive research synthesis. Am J Psychiatry, 1999, 156:1686-1696.
  • 5Haffner SM, Miettinen H, Stern MP. The homeostasis model in the San Antonio heart study. Diabetes Care, 1997, 20: 1087-1092.
  • 6Bailey CJ, Turner RC. Mefformin. N Engl J Med, 1996, 334: 574-579.
  • 7Nestler JE, Beer NA, Jakubowicz D J, et al. Effects of a reduction in circulating insulin by mefformin on serum dehydroepiandresterone sulfate in nondiabetic men. J Clin Endocrinol Metab, 1994, 78:549-554.
  • 8Baptista T, Rangel N, Fernández V, et al. Metformin as an adjunctive treatment to control body weight and metabolic dysfunction during olanzapine administration: a multicentric, double-blind, placebo-controlled trial. Schizophr Res, 2007, 93 ( 1/3 ) :99-108.
  • 9Baptista T. Body weight gain induced by antipsychotic drugs: mechanisms and management. Acta Psychiatr Scand, 1999, 100 : 3-16.
  • 10Yasuda N, Inoue T, Nagakura T, et al. Mefformin causes reduction of food intake and body weight gain and improvement of glucose intolerance in combination with dipeptidyl peptidase IV inhibitor in Zucker fa/fa rats. J Pharmacol Exp Ther, 2004, 310: 614-619.

共引文献56

同被引文献109

  • 1Michael.网坛澳斯卡[J].网球大师,2013,0(3):42-45. 被引量:8
  • 2周媛,王高华.新型抗精神病药对血糖代谢的影响及其机制的研究进展[J].中华精神科杂志,2004,37(4):251-253. 被引量:19
  • 3樊爱珍,王怀海,张瑞国.护理干预对奥氮平致肥胖患者体重的影响[J].护理学杂志(综合版),2005,20(6):42-43. 被引量:4
  • 4杨艳,杨德兰.非典型抗精神病药物所致的体重增加及应对策略[J].重庆医科大学学报,2007,32(8):888-890. 被引量:13
  • 5孙静,牟小冬,李元,王筱兰,尚晓芳,朱荣鑫,张志珺.雷尼替丁防治奥氮平所致体重增加及糖代谢障碍的研究[J].中国神经精神疾病杂志,2007,33(9):560-562. 被引量:13
  • 6Wu RR, Zhao JP, Guo XF, et al. Metformin addition attenuates olanzapine-induced weight gain in drug-naive first-episode schizo- phrenia patients: a double-blind, placebo-controlled study [ J]. Am J Psychiatry, 2008,165 (3) :352-358.
  • 7Behdani F, Hebrani P, Rezaei Ardani A, et al. Effect of topira- mate augmentation in chronic schizophrenia: a placebo-controlled trial[J]. Arch Iran Med, 2011,14(4) :270-275.
  • 8Nickel MK, Nickel C, Muehlbacher M, et al. Influence of topira- mate on olanzapine-related adiposity in women: a random, double- blind, placebo-controlled study [ J ]. J Clin Psychopharmacol, 2005,25 (3) :211-217.
  • 9Narula PK, Rehan HS, Unni KE, et al. Topiramate for prevention of olanzapine associated weight gain and metabolic dysfunction in schizophrenia: a double-blind, placebo-controlled trial [ J ]. Schizoohr Res. 2010.118 ( 1-3 ) :218-223.
  • 10Alvarez-Jimnez M, Gonz61ez-Blanch C, Crespo-Facorro B, et al. Antipsychotic-induced weight gain in chronic and first-episode psy- chotic disorders: a systematic critical reappraisal[ J]. CNS Drugs, 2008,22 (7) :547-562.

引证文献6

二级引证文献48

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部